![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
FOSTER CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
FOSTER CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1...
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.985 | -10.4012671595 | 9.47 | 10.03 | 8.26 | 1428173 | 9.42662478 | CS |
4 | 1.135 | 15.4421768707 | 7.35 | 10.03 | 6.38 | 1328884 | 8.15343614 | CS |
12 | 3.555 | 72.1095334686 | 4.93 | 10.03 | 4.895 | 1129534 | 7.17401432 | CS |
26 | 3.645 | 75.3099173554 | 4.84 | 10.03 | 4.32 | 987447 | 6.87217067 | CS |
52 | 0.595 | 7.5411913815 | 7.89 | 10.03 | 3.26 | 775048 | 6.45138068 | CS |
156 | -0.675 | -7.36899563319 | 9.16 | 14.0435 | 1.45 | 442853 | 7.11281816 | CS |
260 | -8.465 | -49.9410029499 | 16.95 | 28.36 | 1.45 | 401820 | 7.70095277 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions